BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» CF33-hNIS-antiPDL1 shows efficacy in models of gastric cancer peritoneal carcinomatosis
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
CF33-hNIS-antiPDL1 shows efficacy in models of gastric cancer peritoneal carcinomatosis
Jan. 25, 2023
No Comments
Genetically modified derivatives of the chimeric oncolytic virus (OV) CF33 have previously shown cancer selectivity and oncolytic potency against various solid tumors.
BioWorld Science
Conferences
Cancer
Immuno-oncology